Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
To develop and commercialize a vaccine targeting pneumococcus
February 28, 2017
By: Kristin Brooks
Managing Editor, Contract Pharma
Affinivax and Astellas Pharma have entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae (pneumococcus). The partnership will utilize Affinivax’s vaccine technology platform, Multiple Antigen Presenting System (MAPS), to advance a vaccine targeted to prevent and reduce the spread of pneumococcal disease.
Astellas will lead and fund the development program and will obtain worldwide rights to commercialize the MAPS vaccine for pneumococcal disease. Affinivax will receive an initial upfront payment of $10 million and will be eligible to receive development and commercial milestones, as well as royalties on product sales.
“I am pleased to enter into this agreement and partner with Affinivax to develop a pneumococcal vaccine using their novel MAPS technology.” said Kenji Yasukawa, Ph.D., senior vice president and chief strategy officer of Astellas. “Astellas expects to provide a new option to prevent pneumococcal disease with high unmet medical needs by developing innovative MAPS vaccine as part of our commitment to serve patients interests worldwide.”
“We are very pleased that Astellas has recognized the significant potential of our MAPS pneumococcal vaccine,” said Mr. Steven B. Brugger, chief executive officer of Affinivax, Inc. “We are excited to join forces with Astellas to advance a vaccine which can offer such an important global benefit for pneumococcal disease and contribute to Astellas’ impact with its global vaccine franchise”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !